A daily pill to treat covid could be just months away, scientists say

This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation. Within a day of testing positive for covid-19 in June, Miranda Kelly was sick enough to be scared. At 44, with diabetes and high blood pressure, Kelly, a certified nursing assistant, was having trouble breathing, symptoms serious enough to send her to the emergency room.
Picture for A daily pill to treat covid could be just months away, scientists say

6,780 Unapproved Viagra & Cialis Pills Seized by Louisville CBP

Louisville, Kentucky - On Tuesday, September 21, U.S. Customs and Border Protection (CBP) officers in Louisville seized a shipment containing 4,780 unapproved Viagra pills and 2,000 unapproved Cialis pills. The shipment was arriving from Hong Kong and headed to in an individual in Montreal, Quebec Canada. If genuine, and approved by the FDA, the pills would have had an estimated manufacturer’s suggested retail price (MSRP) of more than $460,000.
Arkansas Business

Drug Company OurPharma Plans for Sales Across the US

Adam Kohler hopes that OurPharma LLC of Fayetteville can finally go nationwide. The drug compounding company has licenses from 11 states, including Arkansas, and applications in process in more than 10 others, said Kohler, the company’s executive vice president. But it couldn’t receive a license to sell its pharmaceuticals in...

Pharmaceutical Companies to Represent Key Customer Segment in Lifesciences Enterprise Storage Market Through 2026

Increasing difficulties arising in management and loading of clinical data from lifescience enterprises has propelled the need for adopting effective storage solutions. Leading players in the healthcare-IT industry are introducing effective lifesciences enterprise storage solutions to capture these concerns. Moreover, several lifesciences organizations are adopting cloud-based storage models to share data securely and effectively across multiple landscapes in the healthcare industry. However, growing concerns over the safety of these lifesciences enterprise storage solutions is observed as a key deterrent of their adoption.
Business Insider

Mid-Morning Market Update: Markets Mixed; US Durable Goods Orders Increase Sharply In August

Following the market opening Monday, the Dow traded up 0.65% to 35,024.73 while the NASDAQ fell 0.98% to 14,899.77. The S&P also fell, dropping 0.22% to 4,445.70. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 42,932,210 cases with around 688,040 deaths. India confirmed a total of at least 33,678,780 cases and 447,190 deaths, while Brazil reported over 21,351,970 COVID-19 cases with 594,440 deaths. In total, there were at least 231,898,110 cases of COVID-19 worldwide with more than 4,749,570 deaths, according to data compiled by Johns Hopkins University.

$12.24 Billion in Sales Expected for Sanofi (NASDAQ:SNY) This Quarter

Analysts predict that Sanofi (NASDAQ:SNY) will post $12.24 billion in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Sanofi’s earnings. The lowest sales estimate is $12.17 billion and the highest is $12.30 billion. Sanofi posted sales of $11.08 billion in the same quarter last year, which indicates a positive year-over-year growth rate of 10.5%. The business is expected to report its next earnings results on Thursday, November 4th.
Big Hollywood

Covid treatments: What works, what doesn’t, what might

Overshadowed by the global push for vaccines, the search for treatments for Covid-19 has made steady — if slower — progress. Here is a look at what works, what might work, and what definitely doesn’t. Proven therapies. The World Health Organization (WHO) has approved three types of Covid-19 treatment. The...
Business Insider

NRx Pharma's COVID-19 Candidate Shows Improved Survival At One Year

NRx Pharmaceuticals Inc (NASDAQ:NRXP) has announced top-line data demonstrating improved outcomes at one year in highly comorbid patients with COVID-19 treated with Zyesami. Between June and September 2020, a trial was conducted at a tertiary care hospital involving patients with Critical COVID-19 whose level of comorbidity excluded them from the Phase 2b/3 trial of Zyesami.

Hikma bulks up US injectables business with Custopharm buy

Hikma Pharmaceuticals announced Monday an agreement to purchase Custopharm under a deal potentially worth $425 million, significantly strengthening its US injectables business. Hikma will initially pay $375 million in cash, with a further $50 million payable upon the achievement of certain commercial milestones. Siggi Olafsson, chief executive of Hikma, noted...

Seelos’ SLS-005 Cleared as 5th Arm of HEALEY ALS Trial

Seelos Therapeutics’ experimental therapy SLS-005 (trehalose) will serve as the fifth arm of the multi-regimen HEALEY trial for amyotrophic lateral sclerosis (ALS), after being cleared by the U.S. Food and Drug Administration and the Mass General Brigham Institutional Review Board. With this final regulatory authorization, Seelos may still meet its...

Greece Sends Second Shipment of Humanitarian Aid to Lebanon

ATHENS -- Greece on Monday sent a second shipment of humanitarian aid to Lebanon, which departed for Beirut on the Hellenic Navy's tank landing ship "Lesvos". The shipment was made up of 417 pallets of food, water, baby food, personal hygiene products, Covid-19 personal protection consumables, pharmaceuticals, medical and hospital supplies as well as quantities of military equipment, clothing and spare parts for Lebanon's armed forces.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Expected to Post Earnings of -$0.70 Per Share

Wall Street analysts expect Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) to post ($0.70) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Crinetics Pharmaceuticals’ earnings, with estimates ranging from ($0.74) to ($0.64). Crinetics Pharmaceuticals reported earnings per share of ($0.56) in the same quarter last year, which indicates a negative year over year growth rate of 25%. The company is scheduled to report its next earnings results on Friday, November 5th.

Large cap cos keep Dhaka stocks afloat

Dhaka stocks gained marginally on Monday despite a fall in share prices of most of the companies as a section of investors went for buying shares, especially those of large capitalised companies while many others remained cautious on the trading floor. DSEX, the key index of the Dhaka Stock Exchange,...

Conatus Pharmaceuticals Inc. (NASDAQ: CNAT): Growth Slowdown But Still Better Than Its Peers:

The Healthcare stock closed with direction of ↑ of its last trading at $0.45 while performing a change of 4.38% Gain on Tuesday, January 21, 2020. If one intends to pursue a career as a trader, then one must understand and choose between two basic categories of trading i.e. day trading vs swing trading. Nevertheless, the eventual aim in the case of a day trader or a swing trader remains the same which is to generate profits.

12 Health Care Stocks Moving In Monday's Pre-Market Session

Syndax Pharmaceuticals (NASDAQ:SNDX) shares moved upwards by 8.94% to $20.48 during Monday's pre-market session. The company's market cap stands at $995.9 million. Chemomab Therapeutics (NASDAQ:CMMB) shares rose 7.8% to $12.98. The market value of their outstanding shares is at $147.9 million. Athenex (NASDAQ:ATNX) stock rose 6.83% to $3.44. The market...

Artisan Partners Limited Partnership Has $35.22 Million Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Artisan Partners Limited Partnership cut its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 7.3% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,444,182 shares of the biopharmaceutical company’s stock after selling 113,618 shares during the period. Artisan Partners Limited Partnership owned approximately 0.90% of ACADIA Pharmaceuticals worth $35,224,000 at the end of the most recent quarter.